John Reynolds is Consultant General Surgeon at Beacon Hospital. ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 12 Nov 2026
Overview
Updated 17 Nov 2026
John Reynolds, MD, is Consultant General Surgeon at Beacon Hospital, Dublin. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 17 companies.
- Top research focus: Esophageal Neoplasms
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 17 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 12 Nov 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Point of Care Tests in the Management of Very Early Medical Abortion
Sponsor: University of Edinburgh
- Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
Sponsor: Universitaire Ziekenhuizen KU Leuven
- Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
Sponsor: Karolinska University Hospital
Industry payments
Updated 12 Nov 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Celgene CorporationProgram year20251 payment
- Celgene CorporationProgram year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20232 payments
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Androgen Receptor Inhibitor62.9%Xtandi100%Part D≥13 patientsAromatase Inhibitor37.1%Anastrozole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Background & recognition
Updated 12 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Awards & honors
honors on the public record- Board Member
Oesophageal Cancer Fund
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗
Media & interviews
press, podcasts and appearances- Guest
The Oesophageal Cancer & Barrett's Oesophagus Podcast
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →irishtimes.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH